Medicine on the Fringe: Stem Cell-Based Interventions in Advance of Evidence
Medicine on the Fringe: Stem Cell-Based Interventions in Advance of Evidence
复制标题
DOI：
10.1002/stem.132
复制
发表时间：
2009-01-01
期刊：
影响因子：
5.2
通讯作者：
Mathews, Debra J. H.
中科院分区：
文献类型：
--
作者：
Regenberg, Alan C.;Hutchinson, Lauren A.;Mathews, Debra J. H.
基于干细胞的干预（SCBI）提供了很大的希望;然而，目前几乎没有国际公认的科学证据支持SCBI的临床应用。科学界的共识是，仍有一些障碍需要清除。尽管如此，SCBI目前仍在向患者提供。本文提供了从SCBI提供商获得的材料的内容分析。我们发现的内容，应变轻信和几乎没有证据表明SCBI正在交付的背景下，临床试验。我们的结论是，在科学证据可用之前，作为一般规则，供应商应仅在对照临床试验的背景下提供SCBI。客户应该意识到SCBI的风险和益处是未知的，他们的参与不太可能促进科学知识，他们可能没有资格参加未来的SCBI临床试验。我们建议采取措施促进患者教育并加强全球监督。干细胞2009; 27：2312-2319
Stem cell-based interventions (SCBIs) offer great promise; however, there is currently little internationally accepted, scientific evidence supporting the clinical use of SCBIs. The consensus within the scientific community is that a number of hurdles still need to be cleared. Despite this, SCBIs are currently being offered to patients. This article provides a content analysis of materials obtained from SCBI providers. We find content that strains credulity and almost no evidence of SCBIs being delivered in the context of clinical trials. We conclude that until scientific evidence is available, as a general rule, providers should only offer SCBIs in the context of controlled clinical trials. Clients should be aware that the risks and benefits of SCBIs are unknown, that their participation is unlikely to advance scientific knowledge, and they are likely to become ineligible to participate in future clinical trials of SCBIs. We recommend steps to promote patient education and enhance global oversight. STEM CELLS 2009; 27: 2312-2319